Answers are grounded in this paper and cite their sources.
Analysis shows low COVID-19 vaccine uptake in children, pointing to the need for improved vaccination coverage.
Background In the United States, COVID-19 mRNA vaccines are authorized for use in children aged 6 months to 4 years as a multidose primary series. Although this age group had the highest rate of weekly COVID-19 associated hospitalizations among pediatrics from October 2022-March 2025, there is limited data on vaccine uptake. The aim of this study was to determine the proportion of children aged 1-4 years who were compliant with CDC-recommended 2023-2024 COVID-19 vaccine dose(s). Methods COVID-19 vaccine administration was evaluated among children born between 2019-2022 (ages 1 – 4 in 2023) living in California and Louisiana, two states with mandatory vaccine reporting. We evaluated uptake of the 2023-2024 XBB.1.5-adapted formulation between September 2023-March 2024 and their historical vaccine receipt such as receipt of wildtype or 2022-2023 BA.4/5 bivalent COVID-19 vaccines. Results There were 299,967 children included in the analysis and 6,928 (2.3%) received one mRNA based 2023-2024 COVID-19 vaccine. Among all included children, 2,053 (0.7%) did not receive any doses prior to the 2023-2024 formulation; 605 (0.2%) received one prior dose, 1,834 (0.6%) received 2 prior doses, 2,236 (0.8%) received 3 prior doses and 200 (0.07%) received more than 3 prior doses. Conclusion COVID-19 vaccine uptake in children aged 1-4 years was extremely low. A limited number of children received the 2023-2024 COVID-19 vaccine, and a larger proportion of 2023-2024 vaccinated children had not previously received the recommended multi-dose primary series. Novel approaches to improve vaccination coverage in this vulnerable population are warranted. Disclosures Tara Ahi, MPH, Pfizer Inc.: Employee of Pfizer Inc. and may hold stock or stock options Jazmine S. Mateus, MPH, Pfizer Inc.: Employee of Genesis Research Group, which has received consulting fees from Pfizer Inc. Tiange Yu, MS, Pfizer Inc.: Employee of Genesis Research Group, which has received consulting fees from Pfizer Inc. Anan Zhou, MPH, Pfizer Inc.: Employee of Genesis Research Group, which has received consulting fees from Pfizer Inc. Rajeev M. Nepal, PhD, Pfizer Inc.: Employee of Pfizer Inc. and may hold stock or stock options Mary M. Moran, MD, Pfizer Inc.: Employee of Pfizer Inc. and may hold stock or stock options Alejandro Cané, MD, M.A., Pfizer Inc.: Employee of Pfizer Inc. and may hold stock or stock options Santiago M.C. Lopez, MD, Pfizer Inc.: Employee of Pfizer Inc. and may hold stock or stock options|Pfizer Inc.: Stocks/Bonds (Public Company) Laura A. Puzniak, PhD. MPH, Pfizer Inc.: Employee of Pfizer Inc. and may hold stock or stock options|Pfizer Inc.: Stocks/Bonds (Public Company) Kathleen M. Andersen, PhD, MSc, Pfizer Inc.: Employee of Pfizer Inc. and may hold stock or stock options
No takes yet. Share an insight, caveat, or question.
Ahi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: